Physician profile
Amy E Brumfield
NPI 1477671378
$2,737.59
in general payments reported to CMS, 2019-2025
24 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $366 · 2022: $585 · 2023: $874 · 2024: $467 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.95 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.68 | 2021-2025 | |
| Novo Nordisk INC | $437.40 | 2022-2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $196.89 | 2021-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $178.50 | 2021-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $174.37 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $127.63 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.62 | 2021-2024 | Xifaxan |
| Pfizer INC. | $121.77 | 2022-2025 | |
| Corcept Therapeutics | $90.84 | 2021-2025 | Korlym |
| Becton, Dickinson and Company | $88.64 | 2022-2025 | Bd Onclarity |
| Idorsia Pharmaceuticals US INC | $66.35 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $65.57 | 2023-2024 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.43 | 2021-2022 | |
| Amgen INC. | $48.30 | 2021-2022 | |
| Baxter Healthcare | $44.46 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Ecg Electrode |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $36.15 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.73 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $29.16 | 2021 | |
| Globus Medical, INC. | $27.31 | 2025 | Senza |
| Phathom Pharmaceuticals, INC. | $23.12 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $18.51 | 2022 | |
| Alk-Abello, INC | $18.38 | 2024 | Ragwitek, Odactra, Grastek |
| Novartis Pharmaceuticals Corporation | $16.92 | 2021 | |
| Lucid Diagnostics INC. | $12.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Brumfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.